Literature DB >> 33441112

Daily functioning and symptom factors contributing to attitudes toward antipsychotic treatment and treatment adherence in outpatients with schizophrenia spectrum disorders.

J Leijala1, O Kampman2,3, J Suvisaari4, S Eskelinen5,6.   

Abstract

BACKGROUND: Poor adherence and negative attitudes to treatment are common clinical problems when treating psychotic disorders. This study investigated how schizophrenia core symptoms and daily functioning affect treatment adherence and attitudes toward antipsychotic medication and to compare patients using clozapine or other antipsychotics.
METHOD: A cross-sectional study with data from 275 patients diagnosed with schizophrenia spectrum disorder. Patients adherence, attitudes, insight and side-effects were evaluated using the Attitudes toward Neuroleptic Treatment scale. Overall symptomology was measured using the Brief Psychiatric Rating Scale (BPRS), the Health of the Nation Outcome Scale (HoNOS). The functioning was assessed using activities of daily living scale, instrumental activities of daily living scale and social functioning of daily living scale.
RESULTS: Self-reported treatment adherence was high. Of the patients, 83% reported using at least 75% of the prescribed medication. Having more symptoms was related with more negative attitude towards treatment. There was a modest association with functioning and treatment adherence and attitude toward antipsychotic treatment. Attitudes affected on adherence in non-clozapine but not in clozapine groups.
CONCLUSION: Early detection of non-adherence is difficult. Systematic evaluation of attitudes toward the treatment could be one way to assess this problem, along with optimized medication, prompt evaluation of side effects and flexible use of psychosocial treatments.

Entities:  

Keywords:  Adherence; Attitudes toward neuroleptic treatment scale; Clozapine; Compliance; Psychotic disorder

Year:  2021        PMID: 33441112      PMCID: PMC7805157          DOI: 10.1186/s12888-021-03037-0

Source DB:  PubMed          Journal:  BMC Psychiatry        ISSN: 1471-244X            Impact factor:   3.630


  56 in total

1.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION.

Authors:  S KATZ; A B FORD; R W MOSKOWITZ; B A JACKSON; M W JAFFE
Journal:  JAMA       Date:  1963-09-21       Impact factor: 56.272

2.  Disability assessment in population surveys: results of the O.E.C.D. Common Development Effort.

Authors:  J R McWhinnie
Journal:  Rev Epidemiol Sante Publique       Date:  1981       Impact factor: 1.019

3.  Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia.

Authors:  Diego Novick; Josep Maria Haro; David Suarez; Victor Perez; Ralf W Dittmann; Peter M Haddad
Journal:  Psychiatry Res       Date:  2010-02-24       Impact factor: 3.222

4.  Determination of Adherence Profiles in Schizophrenia Using Self-Reported Adherence: Results From the FACE-SZ Dataset.

Authors:  David Misdrahi; Arnaud Tessier; Joel Swendsen; Fabrice Berna; Lore Brunel; Delphine Capdevielle; Isabelle Chereau; Jean-Marie Danion; Marie De Pradier; Jean-Michel Dorey; Caroline Dubertret; Julien Dubreucq; Catherine Faget; Franck Gabayet; Romain Rey; Raphaelle Richieri; Christine Passerieux; Aurélie Schandrin; Franck Schurhoff; Anne Marie Tronche; Mathieu Urbach; Pierre Michel Llorca; Guillaume Fond
Journal:  J Clin Psychiatry       Date:  2016-09       Impact factor: 4.384

5.  Time-to-First Discontinuation, Adherence and Persistence in New Users of Second-Generation Antipsychotics.

Authors:  Henry C Ndukwe; Prasad S Nishtala
Journal:  J Clin Psychopharmacol       Date:  2016-12       Impact factor: 3.153

6.  Medication adherence of individuals with a first episode of psychosis.

Authors:  E L Coldham; J Addington; D Addington
Journal:  Acta Psychiatr Scand       Date:  2002-10       Impact factor: 6.392

7.  Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.

Authors:  Stefan Leucht; Magdolna Tardy; Katja Komossa; Stephan Heres; Werner Kissling; Georgia Salanti; John M Davis
Journal:  Lancet       Date:  2012-05-03       Impact factor: 79.321

8.  A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients.

Authors:  B Wistedt
Journal:  Acta Psychiatr Scand       Date:  1981-07       Impact factor: 6.392

9.  Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.

Authors:  Joshua A Salomon; Theo Vos; Daniel R Hogan; Michael Gagnon; Mohsen Naghavi; Ali Mokdad; Nazma Begum; Razibuzzaman Shah; Muhammad Karyana; Soewarta Kosen; Mario Reyna Farje; Gilberto Moncada; Arup Dutta; Sunil Sazawal; Andrew Dyer; Jason Seiler; Victor Aboyans; Lesley Baker; Amanda Baxter; Emelia J Benjamin; Kavi Bhalla; Aref Bin Abdulhak; Fiona Blyth; Rupert Bourne; Tasanee Braithwaite; Peter Brooks; Traolach S Brugha; Claire Bryan-Hancock; Rachelle Buchbinder; Peter Burney; Bianca Calabria; Honglei Chen; Sumeet S Chugh; Rebecca Cooley; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Nabila Dahodwala; Adrian Davis; Louisa Degenhardt; Cesar Díaz-Torné; E Ray Dorsey; Tim Driscoll; Karen Edmond; Alexis Elbaz; Majid Ezzati; Valery Feigin; Cleusa P Ferri; Abraham D Flaxman; Louise Flood; Marlene Fransen; Kana Fuse; Belinda J Gabbe; Richard F Gillum; Juanita Haagsma; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Abdullah Hel-Baqui; Hans W Hoek; Howard Hoffman; Emily Hogeland; Damian Hoy; Deborah Jarvis; Ganesan Karthikeyan; Lisa Marie Knowlton; Tim Lathlean; Janet L Leasher; Stephen S Lim; Steven E Lipshultz; Alan D Lopez; Rafael Lozano; Ronan Lyons; Reza Malekzadeh; Wagner Marcenes; Lyn March; David J Margolis; Neil McGill; John McGrath; George A Mensah; Ana-Claire Meyer; Catherine Michaud; Andrew Moran; Rintaro Mori; Michele E Murdoch; Luigi Naldi; Charles R Newton; Rosana Norman; Saad B Omer; Richard Osborne; Neil Pearce; Fernando Perez-Ruiz; Norberto Perico; Konrad Pesudovs; David Phillips; Farshad Pourmalek; Martin Prince; Jürgen T Rehm; Guiseppe Remuzzi; Kathryn Richardson; Robin Room; Sukanta Saha; Uchechukwu Sampson; Lidia Sanchez-Riera; Maria Segui-Gomez; Saeid Shahraz; Kenji Shibuya; David Singh; Karen Sliwa; Emma Smith; Isabelle Soerjomataram; Timothy Steiner; Wilma A Stolk; Lars Jacob Stovner; Christopher Sudfeld; Hugh R Taylor; Imad M Tleyjeh; Marieke J van der Werf; Wendy L Watson; David J Weatherall; Robert Weintraub; Marc G Weisskopf; Harvey Whiteford; James D Wilkinson; Anthony D Woolf; Zhi-Jie Zheng; Christopher J L Murray; Jost B Jonas
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

Review 10.  Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode.

Authors:  Dolores Keating; Stephen McWilliams; Ian Schneider; Caroline Hynes; Gráinne Cousins; Judith Strawbridge; Mary Clarke
Journal:  BMJ Open       Date:  2017-01-06       Impact factor: 2.692

View more
  3 in total

1.  A Comprehensive Monitoring of Clozapine and Related Components in Clinical Practices. Saudi Arabian Scenario.

Authors:  Jisha M Lucca; Fatima M Al-Turaifi; Al-Mubayedh Safyah; Feras A Hamad Al-Awad
Journal:  Psychopharmacol Bull       Date:  2021-11-03

2.  Case Report: Severe Side Effects Following Treatment With First Generation Antipsychotics While Cariprazine Leads to Full Recovery.

Authors:  Maris Taube
Journal:  Front Psychiatry       Date:  2021-12-14       Impact factor: 4.157

Review 3.  Antipsychotic medication for women with schizophrenia spectrum disorders.

Authors:  Bodyl A Brand; Yudith R A Haveman; Franciska de Beer; Janna N de Boer; Paola Dazzan; Iris E C Sommer
Journal:  Psychol Med       Date:  2021-11-12       Impact factor: 10.592

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.